Sterile Fill Finish

  • Sterile Fill Finish 1
  • Sterile Fill Finish 2
  • Sterile Fill Finish 3
Product Description

Eramol specialises in early-phase sterile fill-finish, including aseptic processing, terminal sterilisation, sterile vial manufacturing, clinical packaging, UK & EU QP release and clinical trial supply.

Aseptic and Terminal sterilisation small molecule large molecule/biologics ADCs ATMPS Cell & Gene Therapy Peptides Oligonucleotides Radiopharma Viral Vectors

https://eramol.com/clinical-services/sterile-manufacturing/aseptic/

https://eramol.com/clinical-services/sterile-manufacturing/terminal-sterilisation/

https://eramol.com/clinical-services-category/non-sterile-manufacturing/

https://eramol.com/why-low-line-losses-matter-in-early-phase-sterile-fill-finish/

https://eramol.com/sevenoaks-sterile/

Read more Show less

Eramol

  • Country/Region:
    United Kingdom
  • Founded:
    2013
  • On CPHI since:
    2026
  • Certificates:
    4
  • Employees:
    25 - 49
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
View company profile
Categories
more categories Show less
Specifications
  • Details
    Eramol specialises in early-phase sterile fill-finish, including aseptic processing, terminal sterilisation, sterile vial manufacturing, clinical packaging, UK & EU QP release and clinical trial supply.

    Aseptic and Terminal sterilisation

    small molecule
    large molecule/biologics
    ADCs
    ATMPS
    Cell & Gene Therapy
    Peptides
    Oligonucleotides
    Radiopharma
    Viral Vectors

    https://eramol.com/clinical-services/sterile-fill-finish/end-to-end-early-phase-sterile-fill-finis...
  • Selling Points
    End to End clinical manufacturing

    Manufacture, packaging, labelling, QC testing, QP Release, storage & global distribution capabilities 

    https://eramol.com/about/client-centric-end-to-end-approach/
More specifications Fewer specifications

Eramol

  • Country/Region:
    United Kingdom
  • Founded:
    2013
  • On CPHI since:
    2026
  • Certificates:
    4
  • Employees:
    25 - 49
Company types
CMO/CDMO
Primary activities
Contract Manufacturer
View company profile

More Products from Eramol (4)

  • Non Sterile Manufacturing

    Product Non Sterile Manufacturing

    Oral dosage forms (tablets, capsules, oral liquids)Actives and placebos
  • Packaging & Labelling

    Product Packaging & Labelling

    Primary and Secondary packaging and labelling capabilities 

    https://eramol.com/clinical-services-category/clinical-packaging/

    https://eramol.com/clinical-services-category/labelling-solutions/
  • QP Release

    Product QP Release

    QP Release into UK & EU market

    https://eramol.com/clinical-services-category/eu-uk-qp-release/
  • Storage & Distribution

    Product Storage & Distribution

    Storage and global distribution capabilities 

    https://eramol.com/clinical-services-category/clinical-storage-distribution/

Eramol resources (2)

  • Why low line losses are especially important in early-phase clinical trials

    News Why low line losses are especially important in early-phase clinical trials

    Early-phase sterile fill-finish programmes often rely on limited quantities of valuable drug substance. Low line losses help maximise finished units, reduce API waste and improve clinical supply confidence. By combining efficient process design, Grade A isolator technology and experienced technical oversight, Eramol helps sponsors protect valuable material while supporting high-quality aseptic processing, terminal sterilisation and early-phase sterile manufacturing.
    16 Jul 2026
  • New Sterile Manufacturing Facility (End to End CMO service)

    News New Sterile Manufacturing Facility (End to End CMO service)

    Eramol’s new sterile manufacturing facility at its Sevenoaks campus is a purpose-built, EU GMP Annex 1 aligned site designed to support early-phase sterile injectable programmes. The facility features isolator-based aseptic fill-finish and terminal sterilisation, with phase-appropriate batch sizes and a strong focus on sterility assurance and product protection, achieving <1% line losses. Fully integrated with Eramol’s wider services, the facility provides an end-to-end sterile solution including packaging and labelling, QC testing, UK/EU QP release, regulatory support, GMP/GDP storage and global distribution, with planned expansion to support later-stage and commercial manufacturing.
    22 Jan 2026